Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Dec 2024
The expanded indication is approved to reduce excess body weight and maintain reduction long-term in children 2 years and up with obesity due to BBS, POMC, or LEPR deficiency.
Read Full NewsEnhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection
Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights
Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
"Combinations represent additional options for early-line treatment," researcher says
The bispecific T-cell engager also reduced toxicity in newly diagnosed kids
A combination of clinician and patient prompts worked best, but talks remained infrequent
1.
Radioactive ion beams successfully treat animal tumors in study
2.
A computer-aided diagnostic system for improved detection of breast cancer.
3.
Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.
4.
Study reveals that older women frequently receive an incorrect breast cancer diagnosis.
5.
Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer
1.
The Impact of Microadenoma on Hormonal Health
2.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
3.
ctDNA in Oncology: Transforming MRD Assessment, Disease Tracking, and Early Cancer Detection
4.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
5.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
2.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge